Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Eli Lilly.

    Client Virtual Booth

    ELI LILLY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Eli Lilly
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Lilly Corporate Center, Indianapolis, Indiana 46285
    Telephone
    Telephone
    +1-317-276-2000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lilly.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eli-lilly-and-company/
    Twitter
    Twitter
    https://twitter.com/LillyPad

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tirzepatide Reduced Sleep Apnea Severity by Up to Nearly Two-Thirds in Adults with Obstructive Sleep Apnea (OSA) and Obesity

    Details:

    Zepbound (tirzepatide) injection acts by activating both, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors. It is being evaluated for obstructive sleep apnea & obesity.


    Lead Product(s): Tirzepatide

    Therapeutic Area: Sleep Product Name: Zepbound

    Highest Development Status: Phase IIIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 17, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Results Announced from EMPACT-MI Phase III Trial Investigating the Effect of Jardiance® (empagliflozin) on Risk of Heart Failure Hospitalization and De...

    Details:

    Jardiance (empagliflozin) is an oral inhibitor of sodium-glucose co-transporter 2 (SGLT2) inhibitor, which is being evaluated for the treatment of myocardial infarction.


    Lead Product(s): Empagliflozin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: Boehringer Ingelheim GmbH

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 06, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    More Than Two-Thirds of People with Atopic Dermatitis and Skin of Color Experienced Skin Improvement in a First-Of-Its-Kind Lebrikizumab Study

    Details:

    Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.


    Lead Product(s): Lebrikizumab

    Therapeutic Area: Dermatology Product Name: Ebglyss

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 10, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimers

    Details:

    LY3002813 (donanemab) is a humanized IgG1 monoclonal antibody targeted against an epitope at the N-terminal of a specific type of amyloid beta (Aβ) - which is found only in the brain amyloid plaques associated with Alzheimer's Disease (AD).


    Lead Product(s): Donanemab

    Therapeutic Area: Neurology Product Name: LY3002813

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab

    Details:

    LY3002813 (donanemab) Is a humanized IgG1 monoclonal antibody targeted against an epitope at the N-terminal of a specific type of amyloid beta (Aβ) - which is found only in the brain amyloid plaques associated with Alzheimer's Disease (AD).


    Lead Product(s): Donanemab

    Therapeutic Area: Neurology Product Name: LY3002813

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

    Details:

    FHD-909 is a first-in-class oral BRM selective inhibitor. It is being evaluated in preclinical studies for the treatment of BRG1 mutated non-small cell lung cancer.


    Lead Product(s): FHD-909

    Therapeutic Area: Oncology Product Name: FHD-909

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Foghorn Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Zuellig Pharma Acquires Cialis® (Tadalafil) and Alimta® (Pemetrexed) from Lilly in Select ASEAN Markets

    Details:

    Through the acquisition, Zuellig will have the access for Cialis (tadalafil), used to treat erectile dysfunction, and Alimta (pemetrexed), for the treatment of pleural mesothelioma and non-small cell lung cancer, from Eli Lilly.


    Lead Product(s): Tadalafil

    Therapeutic Area: Psychiatry/Psychology Product Name: Cialis

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Zuellig Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition February 06, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endp...

    Details:

    IBI362 (mazdutide) is a GLP-1R and GCGR dual agonist. It is under phase 3 clinical development for the treatment of adults with overweight or obesity.


    Lead Product(s): Mazdutide

    Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362

    Highest Development Status: Phase IIIProduct Type: Peptide

    Recipient: Innovent Biologics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

    Details:

    IBI362 (mazdutide) is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, which is under phase 3 clinical development for the treatment of obesity.


    Lead Product(s): Mazdutide

    Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362

    Highest Development Status: Phase IIIProduct Type: Peptide

    Recipient: Innovent Biologics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 01, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lilly Completes Acquisition of POINT Biopharma

    Details:

    Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostate cancer.


    Lead Product(s): 177Lu-PNT2002

    Therapeutic Area: Oncology Product Name: PNT2002

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: Point Biopharma

    Deal Size: $1,400.0 million Upfront Cash: $1,400.0 million

    Deal Type: Acquisition December 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search